PNA Innovations
Provides gammaPNA, a cutting edge synthetic nucleic acid technology designed to improve gene detection and regulation.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Acquisition | ||
| Total Funding | 000k | ||
Related Content
PNA Innovations operates as a pharmaceutical technology company from its headquarters in Woburn, Massachusetts. The firm specializes in synthetic biology, focusing on a proprietary nucleic acid platform known as gammaPNA. This technology is engineered for the advanced detection and regulation of genes, as well as the manipulation of nucleic acid structures and functions.
The company's business model revolves around producing custom synthetic nucleic acid sequences for its clients. To manage its specialized operations, PNA Innovations developed a custom, database-driven web application. This system integrates a customer relationship management (CRM) tool with an order and laboratory process tracking system. The platform manages client data, order details, and the status of laboratory procedures, time-stamping all changes for subsequent analysis. It also includes an inventory tracking system that monitors excess product from laboratory runs, reducing waste by alerting chemists when existing inventory can fulfill new orders.
The company has received investment from entities including NeuBase Therapeutics, MAG Ventures, Carnegie Mellon University, and the SBIR program. In a significant milestone, PNA Innovations was acquired by Vera Therapeutics on April 26, 2021.
Keywords: pharmaceutical technology, synthetic biology, nucleic acid platform, gammaPNA, gene detection, gene regulation, custom nucleic acid synthesis, laboratory management software, CRM for biotech, inventory tracking biotech, Vera Therapeutics acquisition, NeuBase Therapeutics, synthetic nucleic acids, gene manipulation